Benzofuroxan Derivatives as Potent Agents against Multidrug-Resistant Mycobacterium tuberculosis. 2021

Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara Jaú Highway KM 01, 14800903, Araraquara, Brazil.

Tuberculosis (TB) is currently the leading cause of death related to infectious diseases worldwide, as reported by the World Health Organization. Moreover, the increasing number of multidrug-resistant tuberculosis (MDR-TB) cases has alarmed health agencies, warranting extensive efforts to discover novel drugs that are effective and also safe. In this study, 23 new compounds were synthesized and evaluated in vitro against the drug-resistant strains of M. tuberculosis. The compound 6-((3-fluoro-4-thiomorpholinophenyl)carbamoyl)benzo[c][1,2,5]oxadiazole 1-N-oxide (5 b) was particularly remarkable in this regard as it demonstrated MIC90 values below 0.28 μM against all the MDR strains evaluated, thus suggesting that this compound might have a different mechanism of action. Benzofuroxans are an attractive new class of anti-TB agents, exemplified by compound 5 b, with excellent potency against the replicating and drug-resistant strains of M. tuberculosis.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001583 Benzoxazoles Benzoxazole
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug

Related Publications

Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
April 2024, RSC medicinal chemistry,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
August 2019, European journal of medicinal chemistry,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
January 2013, Chemical & pharmaceutical bulletin,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
February 2010, Bioorganic & medicinal chemistry,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
February 2021, European journal of medicinal chemistry,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
September 2007, Bioorganic & medicinal chemistry letters,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
June 2008, Journal of chemotherapy (Florence, Italy),
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
September 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
October 2019, Scientific reports,
Guilherme F S Fernandes, and Débora L Campos, and Isabel C Da Silva, and João L B Prates, and Aline R Pavan, and Fernando R Pavan, and Jean L Dos Santos
August 2011, Molecules (Basel, Switzerland),
Copied contents to your clipboard!